Source: Eur Respir J 2014; 44: 1308-1318
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tiddens Harm A.W.M., Bos Aukje C., Mouton Johan W., Devadason Sunalene, Janssens Hettie M.. Inhaled antibiotics: dry or wet?. Eur Respir J 2014; 44: 1308-1318

Member's Comments

No comment yet.

Related content which might interest you: Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008 Difference in resistance to humidity between commonly used dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Treating acute cough: wet versus dry – have we got the paradigm wrong? Source: ERJ Open Res 2015; 1: 00055-2015 Year: 2015 Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005 Steroids in COPD: still up in the air? Source: Eur Respir J 2010; 35: 949-951 Year: 2010 Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002 Inhaled therapies: can they breathe new life into asthma? Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006 Inhaled medication: which device for which patient? Source: Eur Respir Monogr 2015; 69: 213-223 Year: 2015 Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002 Systemic activity of two different dry powder combinations of inhaled corticosteroids and long-acting β2-agonists in children with asthma assessed by knemometry Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy Year: 2012 Inhaled corticosteroids reduce growth. Or do they? Source: Eur Respir J 2001; 17: 287-294 Year: 2001 Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Inhaled corticosteroids in COPD: the final verdict is… Source: Eur Respir J, 52 (6) 1801940; 10.1183/13993003.01940-2018 Year: 2018 Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013